These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 11138685

  • 41. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM, Wörmann B, Gramatzki M, Riggert J, Gratz S, Béhé M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [Abstract] [Full Text] [Related]

  • 42. Targeting of a head and neck squamous cell carcinoma xenograft model using the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linker.
    Cheng J, Persson M, Tolmachev V, Siavaev I, Orlova A, Kairemo K, Anniko M.
    Acta Otolaryngol; 2004 Nov; 124(9):1078-85. PubMed ID: 15513553
    [Abstract] [Full Text] [Related]

  • 43. Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies.
    DeNardo DA, DeNardo GL, Yuan A, Shen S, DeNardo SJ, Macey DJ, Lamborn KR, Mahe M, Groch MW, Erwin WD.
    J Nucl Med; 1996 Dec; 37(12):1970-5. PubMed ID: 8970516
    [Abstract] [Full Text] [Related]

  • 44. Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10.
    Weiden PL, Breitz HB, Seiler CA, Bjorn MJ, Ratliff BA, Mallett R, Beaumier PL, Appelbaum JW, Fritzberg AR, Salk D.
    J Nucl Med; 1993 Dec; 34(12):2111-9. PubMed ID: 8254397
    [Abstract] [Full Text] [Related]

  • 45. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations.
    de Klerk JM, van het Schip AD, Zonnenberg BA, van Dijk A, Stokkel MP, Han SH, Blijham GH, van Rijk PP.
    J Nucl Med; 1994 Sep; 35(9):1423-8. PubMed ID: 8071686
    [Abstract] [Full Text] [Related]

  • 46. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.
    Kotzerke J, Glatting G, Seitz U, Rentschler M, Neumaier B, Bunjes D, Duncker C, Dohr D, Bergmann L, Reske SN.
    J Nucl Med; 2000 Mar; 41(3):531-7. PubMed ID: 10716329
    [Abstract] [Full Text] [Related]

  • 47. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.
    Deb N, Goris M, Trisler K, Fowler S, Saal J, Ning S, Becker M, Marquez C, Knox S.
    Clin Cancer Res; 1996 Aug; 2(8):1289-97. PubMed ID: 9816299
    [Abstract] [Full Text] [Related]

  • 48. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
    Behr TM, Sgouros G, Stabin MG, Béhé M, Angerstein C, Blumenthal RD, Apostolidis C, Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
    [Abstract] [Full Text] [Related]

  • 49. Radiolabeled antibody combined with external radiotherapy for the treatment of head and neck cancer: reconstruction of a theoretical phantom of the larynx for radiation dose calculation to local tissues.
    Maraveyas A, Myers M, Stafford N, Rowlinson-Busza G, Stewart JS, Epenetos AA.
    Cancer Res; 1995 Mar 01; 55(5):1020-7. PubMed ID: 7866985
    [Abstract] [Full Text] [Related]

  • 50. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
    Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, Desjardins A, Sampson JH, Gururangan S, Wong TZ, Badruddoja MA, Zhao XG, Bigner DD, Zalutsky MR.
    J Nucl Med; 2006 Jun 01; 47(6):912-8. PubMed ID: 16741299
    [Abstract] [Full Text] [Related]

  • 51. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME, Stadtmauer E, Hajjar G, Sharkey RM, Suleiman S, Luger S, Swayne LC, Alavi A, Goldenberg DM.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [Abstract] [Full Text] [Related]

  • 52. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
    Mulligan T, Carrasquillo JA, Chung Y, Milenic DE, Schlom J, Feuerstein I, Paik C, Perentesis P, Reynolds J, Curt G.
    Clin Cancer Res; 1995 Dec 01; 1(12):1447-54. PubMed ID: 9815943
    [Abstract] [Full Text] [Related]

  • 53. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol.
    Visser GW, Gerretsen M, Herscheid JD, Snow GB, van Dongen G.
    J Nucl Med; 1993 Nov 01; 34(11):1953-63. PubMed ID: 8229241
    [Abstract] [Full Text] [Related]

  • 54. Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.
    Hajjar G, Sharkey RM, Burton J, Zhang CH, Yeldell D, Matthies A, Alavi A, Losman MJ, Brenner A, Goldenberg DM.
    Clin Colorectal Cancer; 2002 May 01; 2(1):31-42. PubMed ID: 12453334
    [Abstract] [Full Text] [Related]

  • 55. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
    Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ.
    Clin Cancer Res; 2003 May 01; 9(5):1639-47. PubMed ID: 12738716
    [Abstract] [Full Text] [Related]

  • 56. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
    Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, Stabin MG, Sgouros G, American Association of Physicists in Medicine.
    J Nucl Med; 2004 Oct 01; 45(10):1725-33. PubMed ID: 15471841
    [Abstract] [Full Text] [Related]

  • 57. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions.
    Richman CM, DeNardo SJ, O'Grady LF, DeNardo GL.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5916s-5920s. PubMed ID: 7493370
    [Abstract] [Full Text] [Related]

  • 58. 186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice.
    Beaumier PL, Venkatesan P, Vanderheyden JL, Burgua WD, Kunz LL, Fritzberg AR, Abrams PG, Morgan AC.
    Cancer Res; 1991 Jan 15; 51(2):676-81. PubMed ID: 1845957
    [Abstract] [Full Text] [Related]

  • 59. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA.
    J Nucl Med; 2006 Jul 15; 47(7):1127-35. PubMed ID: 16818947
    [Abstract] [Full Text] [Related]

  • 60. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
    Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, Nanus DM, Bander NH.
    J Nucl Med; 2005 May 15; 46(5):850-8. PubMed ID: 15872360
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.